Roll No. | | | | | | | | | | | | |

Total No. of Pages : 02

Total No. of Questions : 10

B.Pharma (2011 to 2016) (Sem.–8)

PHARMACEUTICS-IX (DOSAGE FORM DESIGN)

Subject Code : BPHM-801

Paper ID : [72296]

Time : 3 Hrs. Max. Marks : 80

INSTRUCTION TO CANDIDATES :

1. SECTION-A is COMPULSORY consisting of FIFTEEN questions carrying TWO marks each.
2. SECTION-B contains FIVE questions carrying FIVE marks each and students have to attempt any FOUR questions.
3. SECTION-C contains FOUR questions carrying TEN marks each and students have to attempt any THREE questions.

SECTION-A

1. Answer briefly :

a. Define bioavailability.

b. Define angle of repose.

c. Define enantiotropic polymorph.

d. Define solvates.

e. Name any two drugs prone to oxidation.

f. Explain hydrates.

g. Define pKa.

h. Discuss the importance of student's T test.

i. Define sustained release formulation.

j. Give examples of dosage forms exempted from bioequivalence testing.

k. Name any two approaches for solubility enhancement.

l. Define absolute and relative bioavailability.

m. Define osmotic tablets.

n. Define therapeutic index.

o. Define implants.

SECTION-B

2. What are the polymers used for extended release tablets? Discuss the *in vitro* testing of extended release tablets.

3. Explain the rationale for retrospective validation. Also, discuss the process briefly.

4. Discuss various factors affecting the oxidation of drugs.

5. What is BCS? Discuss various classes along with suitable example.

6. What are the prominent features of quality assurance?

SECTION-C

7. Discuss importance of pH and pka at the site of absorption. Enlist the various properties of the drugs to be considered while performing the preformulation studies.

8. Discuss the ICH guidelines for accelerated stability studies

9. What are implants? Discuss implants with few commercialised examples.

10. Discuss the prominent features of cGMP related to manufacturing of tablets.